Last reviewed · How we verify
Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies the safety of alternating ixazomib citrate and lenalidomide as treatment to help keep cancer from coming back after stem cell transplant (maintenance therapy) in treating patients with multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stimulate the immune system to attack cancer cells. Giving ixazomib citrate and lenalidomide as maintenance therapy after transplant may prolong the length of time until the cancer returns.
Details
| Lead sponsor | Fred Hutchinson Cancer Center |
|---|---|
| Phase | PHASE2 |
| Status | COMPLETED |
| Enrolment | 30 |
| Start date | Wed Dec 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Oct 24 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Plasma Cell Myeloma
- Transplant-Related Carcinoma
Interventions
- Ixazomib Citrate
- Laboratory Biomarker Analysis
- Lenalidomide
Countries
United States